# Anticoagulation in Critically Ill Patients With COVID-19 (The IMPACT Trial)

> **NCT04406389** · PHASE4 · TERMINATED · sponsor: **Weill Medical College of Cornell University** · enrollment: 14 (actual)

## Conditions studied

- COVID-19

## Interventions

- **DRUG:** Enoxaparin sodium
- **DRUG:** Unfractionated heparin
- **DRUG:** Fondapariniux
- **DRUG:** Argatroban

## Key facts

- **NCT ID:** NCT04406389
- **Lead sponsor:** Weill Medical College of Cornell University
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-10-13
- **Primary completion:** 2021-04-17
- **Final completion:** 2022-04-21
- **Target enrollment:** 14 (ACTUAL)
- **Why stopped:** Low accrual
- **Last updated:** 2023-09-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04406389

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04406389, "Anticoagulation in Critically Ill Patients With COVID-19 (The IMPACT Trial)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04406389. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*